Isoquercetin Composition for PDI-Targeted Sickle Cell Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease are inadequate in effectively managing the symptoms and progression of the condition, particularly due to the involvement of extracellular protein disulfide isomerase (PDI) in thrombo-inflammatory vasculopathy.
Innovation Solution
Administering a composition comprising isoquercetin, vitamin B3, and vitamin C, optionally with folic acid, which exhibits synergistic effects in reducing symptoms and progression of sickle cell disease by inhibiting PDI and addressing associated thrombo-inflammatory processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for sickle cell disease, then current standard of care is maintained, but the symptoms and progression of the condition are not effectively managed
Solution Approach 1:
The patent combines multiple active ingredients (quercetin, vitamin B3, vitamin C, and optionally folic acid) into a single pharmaceutical composition. This combination approach allows the synergistic interaction of different mechanisms to collectively address the complex pathophysiology of sickle cell disease, particularly targeting PDI inhibition and thrombo-inflammatory processes that conventional single-agent treatments cannot effectively manage alone.
Solution Approach 2:
The patent modifies the treatment approach by changing the biochemical parameters of the treatment regimen through the use of specific active ingredients with known mechanisms of action. Quercetin and vitamin B3 specifically inhibit PDI, while vitamin C provides antioxidant protection, collectively altering the biochemical environment to reduce thrombo-inflammatory vasculopathy and improve symptom management effectiveness.
2Reliability
If PDI is inhibited to reduce thrombo-inflammatory vasculopathy, then symptom management improves, but the complexity of treatment regimen increases
Solution Approach 1:
Multiple active ingredients with different mechanisms of action are merged into a single pharmaceutical composition. This combination includes PDI inhibitors (quercetin, vitamin B3) and antioxidant agents (vitamin C), allowing simultaneous targeting of multiple pathogenic mechanisms through one treatment regimen rather than requiring multiple separate medications, thereby reducing overall treatment complexity.
Solution Approach 2:
The pharmaceutical composition is designed to perform multiple functions simultaneously: PDI inhibition to reduce thrombo-inflammatory vasculopathy, antioxidant protection to prevent oxidative stress damage, and synergistic enhancement of overall therapeutic effect. This multi-functionality allows a single treatment regimen to address multiple aspects of sickle cell disease pathophysiology.
Data Source
AI summary
Disclosed are compositions and methods for treating sickle cell disease. Also disclosed are methods of treating sickle cell disease comprising administering to a subject in need thereof an effective amount of isoquercetin, vitamin B3, vitamin C, and optionally folic acid and wherein the effective amount is sufficient to halt progression of one or more of the symptoms of sickle cell disease.